Biopharma Insights - page 7

17 Companies Pioneering AI Foundation Models in Pharma and Biotech

Foundation models represent a relatively new paradigm in artificial intelligence (AI), revolutionizing how machine learning models are developed and deployed. Foundation models are a class of large-scale machine learning models, typically …

Continue ›››

Why AI Needs to Be at the Center of mRNA Design

One of the biggest hurdles in mRNA development is the in vitro to in vivo gap; results that look strong in lab models often fail to translate in living systems. …

Continue ›››

How Tech Giants like NVIDIA, Google, and Microsoft Are Targeting New Niches in Biopharma R&D

Tech giants are becoming part of biopharma’s infrastructure, applying AI, data, and cloud to drug discovery as they seek footholds in new markets. Large technology companies aren’t newcomers to biopharma …

Continue ›››

Phesi Reports GLP-1 Trials Now Span 100+ Diseases

Phesi has published an analysis showing that GLP-1 drugs are now being tested across more than 100 diseases, extending well beyond their established use in diabetes and obesity. The findings …

Continue ›››

Biotech in Space: Microgravity, Ventures, and the Path to Production

From public labs to private stations, the near-term outlook for orbital bioprocessing and its first commercial pipelines The renewed surge in space ambition extends beyond rockets and habitats by driving …

Continue ›››

Digital Twins in Rare Diseases: From Virtual Trials to Personalized Care

Digital twins are moving from aerospace, automotive, and manufacturing into medicine and drug development, with the potential to transform how we study diseases, conduct clinical trials, and personalize treatment and …

Continue ›››

How AI Is Transforming Medicinal Chemistry: From Discovery to Manufacturing

In medicinal chemistry, the “make” stage of the design–make–test–analyze (DMTA) cycle is often where good ideas go to die. Synthetic bottlenecks, expensive building blocks, low-yield reactions, and complications during scale-up …

Continue ›››

Digital Pathology: Slides, AI, & Challenges

Pathology has progressed from glass slides to AI-driven digital diagnostics, promising to transform disease detection while facing adoption and market challenges Bo Wang, Head of Biomedical AI at Xaira Therapeutics, puts it …

Continue ›››

Building the Virtual Cell: AI Foundation Models and Billion-Cell Datasets

From early 2000s and a 2012 milestone to a decade-long quiet—virtual cell modeling is resurging with transformers, perturbation atlases, and lab-in-the-loop systems While the term “virtual cell” initially goes back …

Continue ›››

H1 2025 Recap: Key Signals from the Tech+Bio Frontier

A high-signal summary of some of the most important moves and trends shaping biotech and tech-enabled life sciences in the first half of 2025. In this issue: Financial Climate & …

Continue ›››

"AI Scientists" - New Collaborators for Rare Disease Research?

In the quest to understand and treat the over 6,000 rare diseases, researchers encounter a number of limitations – in the amount of available data, access to interdisciplinary expertise, and …

Continue ›››

What are Foundation Models in Biology and Healthcare?

Content: History of AI in the Context of Foundation Models The Technology Stack Behind Foundation Models The Paradigm Shift in Biomedical Research and Drug Discovery Challenges of Foundation Models in …

Continue ›››